The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system

Abbi L. Engel, Gregory E. Holt, Hailing Lu

Research output: Contribution to journalReview articlepeer-review

90 Scopus citations


Toll-like receptor (TLR) ligation activates both the innate and adaptive immune systems, and plays an important role in antiviral and anti-tumor immunity. Therefore, a significant amount of effort has been devoted to exploit the therapeutic potential of TLR agonists. Depending on the therapeutic purpose, either as adjuvants to vaccine, chemotherapy or standalone therapy, TLR agonists have been administered via different routes. Both preclinical and clinical studies have suggested that the route of administration has significant effects on pharmacokinetics, and that understanding these effects is critical to the success of TLR agonist drug development. This article will summarize the pharmacokinetics of TLR agonists with different administration routes, with an emphasis on clinical studies of TLR ligands in oncologic applications.

Original languageEnglish (US)
Pages (from-to)275-289
Number of pages15
JournalExpert review of clinical pharmacology
Issue number2
StatePublished - Mar 2011


  • CpG
  • imiquimod
  • immune response
  • immunotherapy
  • pharmacokinetics
  • poly I:C
  • resiquimod
  • TLR agonist
  • Toll-like receptor

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system'. Together they form a unique fingerprint.

Cite this